featured
FDA Revises Recommendation for Metformin Use in Patients With Chronic Kidney Disease
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients With Reduced Kidney Function
- FDA Issues New Warning for Two Diabetes Medications
- Metformin-Containing Drugs: Drug Safety Communication - Revised Warnings for Certain Patients With Reduced Kidney Function
- Food and Drug Administration. Metformin-containing drugs: drug safety communication - revised warnings for certain patients with reduced kidney function. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm494829.htm. Accessed on April 12, 2016.
- Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: http://www.fda.gov/Drugs/DrugSafety/ ucm493244.htm. Accessed on April 12, 2016.
- Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34(6):1431-1437.
- Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312(24):2668-2675.
Disclosure statements are available on the authors' profiles: